STOCKHOLM, Aug 1, 2018 /PRNewswire/ -- Cantargia AB announce that the Chinese patent authority, State Intellectual Property Office ("SIPO") has issued a formal approval concerning the company's patent application of the immuno-oncological antibody CAN04 (nidanilimab). CAN04 binds...
from PR Newswire: //https://ift.tt/2Kh7wSq
No comments:
Post a Comment